U.S. patent office drops pharma-disputed regs; FDA nixes broader use of Spectrum's Fusilev;

> The U.S. Patent and Trademark Office has dropped regulations that sparked a lawsuit by GlaxoSmithKline and the two sides have asked a court to dismiss the suit. Report

> FDA declined Spectrum Pharmaceuticals' request to broaden use of its drug, Fusilev, to treat advanced metastatic colorectal cancer. Report

> Sanofi-Aventis and Merck KGaA are among international drugmakers expected to bid for iNova Pharmaceuticals, the Australian Financial Review said. Report

> More reason for older patients to get the herpes zoster vaccine: Researchers found that adults who get singles have a 30 percent greater risk of developing a stroke. Report

> Zantac 75, the GlaxoSmithKline-owned heartburn brand, is launching a press and radio campaign to drive awareness and differentiate it from competitor brands. Report

Biotech News:

> Amgen looks to boost its R&D success rate. Article

> Avanir unveils promising late-stage Zenvia data. Article

> FDA staffers question Acorda's MS drug. Article

> Quebec to make $123M biopharma investment Article

> Kansas spurs early-stage drug development with $50M in VC funding Article

And Finally... Swine flu drove a 15-fold increase in intensive care admissions for viral lung inflammation in Australia and New Zealand, a study found. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.